Research Article

Blood, Lymphatics, Immune System and Stem Cells

Disruption of direct 3D telomere–TRF2 interaction through two molecularly disparate mechanisms is a hallmark of primary Hodgkin and Reed–Sternberg cells

  • Laboratory Investigation volume 97, pages 772781 (2017)
  • doi:10.1038/labinvest.2017.33
  • Download Citation


In classical Hodgkin’s lymphoma (cHL), specific changes in the 3D telomere organization cause progression from mononuclear Hodgkin cells (H) to multinucleated Reed–Sternberg cells (RS). In a post-germinal center B-cell in vitro model, permanent latent membrane protein 1 (LMP1) expression, as observed in Epstein–Barr virus (EBV)-associated cHL, results in multinuclearity and complex chromosomal aberrations through downregulation of key element of the shelterin complex, the telomere repeat binding factor 2 (TRF2). Thus, we hypothesized that the three-dimensional (3D) telomere–TRF2 interaction was progressively disturbed during transition from H to RS cells. To this end, we developed and applied for the first time a combined quantitative 3D TRF2-telomere immune fluorescent in situ hybridization (3D TRF2/Telo-Q-FISH) technique to monolayers of primary H and RS cells, and adjacent benign internal control lymphocytes of lymph node biopsy suspensions from diagnostic lymph node biopsies of 14 patients with cHL. We show that H and RS cells are characterized by two distinct patterns of disruption of 3D telomere–TRF2 interaction. Disruption pattern A is defined by massive attrition of telomere signals and a considerable increase of TRF2 signals not associated with telomeres. This pattern is restricted to EBV-negative cHL. Disruption pattern B is defined by telomere de-protection due to an impressive loss of TRF2 signals, physically linked to telomeres. This pattern is typical of, but is not restricted to, LMP1+EBV-associated cHL. In the disruption pattern B group, so-called 'ghost' end-stage RS cells, void of both TRF2 and telomere signals, were identified, whether or not associated with EBV. Our findings demonstrate that two molecularly disparate mechanisms converge on the level of 3D telomere–TRF2 interaction in the formation of RS cells.

  • Subscribe to Laboratory Investigation for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    , , et al. Karyotypic dissection of Hodgkin's disease cell lines reveals ectopic subtelomeres and ribosomal DNA at sites of multiple jumping translocations and genomic amplification. Leukemia 2000;14:1803–1814.

  2. 2.

    , , et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer 2003;103:489–495.

  3. 3.

    , , et al. U-HO1, a new cell line derived from a primary refractory classical Hodgkin lymphoma. Cytogenet Genome Res 2007;119:204–210.

  4. 4.

    , , et al. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Haematologica 2008;93:1318–1326.

  5. 5.

    , , et al. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 2010;116:418–427.

  6. 6.

    , , et al. Molecular karyotypes of Hodgkin and Reed-Sternberg cells at disease onset reveal distinct copy number alterations in chemosensitive versus refractory Hodgkin lymphoma. Clin Cancer Res 2011;17:3443–3454.

  7. 7.

    , , et al. The 3D nuclear organization of telomeres marks the transition from Hodgkin to Reed-Sternberg cells. Leukemia 2009;23:565–573.

  8. 8.

    , , et al. Dynamic chromosomal rearrangements in Hodgkin’s lymphoma are due to ongoing three-dimensional nuclear remodeling and breakage-bridge-fusion cycles. Haematologica 2010;95:2038–2046.

  9. 9.

    , , . Genomic instability: the driving force behind refractory/relapsing Hodgkin’s lymphoma. Cancers 2013;5:714–725.

  10. 10.

    , , et al. Differences in nuclear DNA organization between lymphocytes, Hodgkin and Reed-Sternberg cells revealed by structured illumination microscopy. J Cell Biochem 2014;115:1441–1448.

  11. 11.

    , , . DNA superresolution structure of Reed-Sternberg cells differs between long lasting remission versus relapsing Hodgkin’s lymphoma patients. J Cell Biochem 2016;117:1633–1637.

  12. 12.

    . Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005;19:2100–2110.

  13. 13.

    , . Telomeres and telomerase dance to the rhythm of the cell cycle. Trends Biochem Sci 2012;37:391–399.

  14. 14.

    , , et al. LMP1 mediates multinuclearity through downregulation of shelterin proteins and formation of telomeric aggregates. Blood 2015;125:2101–2110.

  15. 15.

    , , et al. In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2. Int J Cancer 2005;113:937–945.

  16. 16.

    , , et al. No DDRama at chromosome ends: TRF2 takes centre stage. Trends Biochem Sci 2015;40:275–285.

  17. 17.

    , , et al. TRF2 and lamin A/C interact to facilitate the functional organization of chromosome ends. Nat Commun 2014;5:5467.

  18. 18.

    , , et al. Chromosomal rearrangements after ex vivo Epstein-Barr virus (EBV) infection of human B cells. Oncogene 2010;29:503–515.

  19. 19.

    , , . Telomere dysfunction and activation of alternative lengthening of telomeres in B-lymphocytes infected by Epstein-Barr virus. Oncogene 2013;32:5522–5530.

  20. 20.

    , , et al. Telomerase activity in reactive and neoplastic lymphoid tissue: infrequent detection of activity in Hodgkin’s disease. Blood 1997;89:26–31.

  21. 21.

    , , et al. Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease overexpress the telomerase RNA template (hTR). J Pathol 1999;188:139–145.

  22. 22.

    , , et al. Possible immortalization of Hodgkin and Reed-Sternberg cells: telomerase expression, lengthening of telomere, and inhibition of apoptosis by NF-kappaB expression. Leuk Lymphoma 2001;42:639–647.

  23. 23.

    , , et al. C-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc Natl Acad Sci USA 2005;102:9613–9618.

  24. 24.

    , , et al. The three-dimensional organization of telomeres in the nucleus of mammalian cells. BMC Biol 2004;2:12.

  25. 25.

    , , . Generalized approach for accelerated maximum likelihood based image restoration applied to three-dimensional fluorescence microscopy. J Microsc 2001;204:99–107.

  26. 26.

    , , et al. Characterizing the three-dimensional organization of telomeres. Cytometry A 2005;67:144–150.

  27. 27.

    , . The significance of telomeric aggregates in the interphase nuclei of tumor cells. J Cell Biochem 2006;97:904–915.

  28. 28.

    , , et al. 3D telomere FISH defines LMP1 expressing Reed-Sternberg cells as end-stage cells with telomere-poor “ghost” nuclei. Lab Invest 2010;90:611–619.

  29. 29.

    , , et al. Alterations of centromere positions in nuclei of immortalized and malignant mouse lymphocytes. Cytometry A 2007;71:386–392.

  30. 30.

    , , et al. TRF2-mediated control of telomere DNA topology as a mechanism for chromosome-end protection. Mol Cell 2016;61:274–286.

  31. 31.

    , , et al. Loss of lamin A function increases chromatin dynamics in the nuclear interior. Nat Commun 2015;6:8044.

  32. 32.

    , , et al. Elevated levels of TRF2 induce telomeric ultrafine anaphase bridges and rapid telomere deletions. Nat Commun 2015;6:10132.

  33. 33.

    , , et al. Sp1 upregulates expression of TRF2 and TRF2 inhibition reduces tumorigenesis in human colorectal carcinoma cells. Cancer Biol Ther 2009;8:2166–2174.

  34. 34.

    , , et al. Elevated TRF2 in advanced breast cancers with short telomeres. Breast Cancer Res Treat 2011;127:623–630.

  35. 35.

    , , et al. Increased expression of telomere length regulating factors TRF1, TRF2 and TIN2 in patients with adult T-cell leukaemia. Int J Cancer 2006;119:2090–2097.

  36. 36.

    , , et al. TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nat Cell Biol 2013;15:818–828.

  37. 37.

    , . DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. Nat Cell Biol 2005;7:712–718.

  38. 38.

    , . Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 2007;448:1068–1071.

  39. 39.

    , et al. Hepatocytes with extensive telomere deprotection and fusion remain viable and regenerate liver mass through endoreduplication. Genes Dev 2006;20:2648–2653.

  40. 40.

    , , . Persistent telomere damage induces bypass of mitosis and tetraploidy. Cell 2010;141:81–93.

  41. 41.

    , , et al. Telomere dysfunction causes alveolar stem cell failure. Proc Natl Acad Sci USA 2015;112:5099–5104.

  42. 42.

    , , et al. Mir-23a induces telomere dysfunction and cellular senescence by inhibiting TRF2 expression. Aging Cell 2015;14:391–399.

  43. 43.

    . Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp Hematol 2006;34:399–406.

  44. 44.

    . The biology of Hodgkin’s lymphoma. Nat Rev Cancer 2009;9:15–27.

  45. 45.

    , . Human cancer cells harbour T-stumps, a distinct class of extremely short telomeres. Mol Cell 2007;28:315–327.

  46. 46.

    , , . Oxidative stress enables Epstein-Barr virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular growth-promoting factors. Oncogene 2016;35:3807–3816.

  47. 47.

    , , et al. In situ expression of the IL-1-alpha and TNF-alpha genes by Reed-Sternberg cells in Hodgkin's disease. Int J Cancer 1992;50:689–693.

  48. 48.

    , , et al. Cellular senescence markers p16INK4a and p21CIP1/WAF are predictors of Hodgkin lymphoma outcome. Clin Cancer Res 2015;21:5164–5172.

  49. 49.

    , , et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 2009;11:973–979.

  50. 50.

    , , et al. The telomere deprotection response is functionally distinct from the genomic DNA damage response. Mol Cell 2013;51:141–155.

Download references


We thank Mary Cheang, Biostatistician, for statistical analysis of data. The 3D Telomeres Technology platform (3DTT) and the TeloView are property to 3D Signatures and were used with the company's permission. We are grateful to receive research support from the Cole Foundation (NJ) and the Canadian Institutes of Health Research (SM; Grant MOP110982).

Author information


  1. Division of Hematology, Department of Medicine, Jewish General Hospital, McGill University, Montréal, QC, Canada

    • Hans Knecht
    • , Nathalie A Johnson
    •  & Tina Haliotis
  2. Department of Pathology, Jewish General Hospital, McGill University, Montréal, QC, Canada

    • Tina Haliotis
  3. MICB, University of Manitoba, Winnipeg, MB, Canada

    • Daniel Lichtensztejn
    •  & Sabine Mai


  1. Search for Hans Knecht in:

  2. Search for Nathalie A Johnson in:

  3. Search for Tina Haliotis in:

  4. Search for Daniel Lichtensztejn in:

  5. Search for Sabine Mai in:

Competing interests

SM is a founder of and currently a director, officer (CSO) and shareholder of 3D Signatures. HK is a member of the Scientific Advisory Board and shareholder of 3D Signatures. The remaining authors declare no conflict of interest.

Corresponding author

Correspondence to Hans Knecht.

Supplementary information

Supplementary Information accompanies the paper on the Laboratory Investigation website (